Azilva (azilsartan) / Takeda - LARVOL DELTA

A CASE OF LATE-ONSET NEPHROTIC-RANGE PROTEINURIA CAUSED BY AN ANTI-ANGIOGENIC THERAPY FOR METASTATIC BREAST CANCER (ISN-WCN 2026) - "After changing to epirubicin/cyclophosphamide (EC) regimen, the patient's condition had been rather stable after 6 courses of EC therapy, when nausea and general malaise developed and worsened. Then, the regimen was changed to weekly paclitaxel plus bevacizumab (PTX/BEV) therapy...Because it was considered Grade 3 adverse events due to anti-angiogenic therapy, BEV was discontinued and the patient was followed with azilsartan and dapagliflozin...Conclusion The adverse events due to anti-angiogenic therapy are reported to be high, with proteinuria (∼10% to 60%) and hypertension being most prevalent. The interval between initiation of the therapy and the onset of proteinuria varies significantly (several weeks to ∼1 year), but the present case exhibited apparent proteinuria after 80 weeks of therapy. It is important to continuously follow up with close attention to renal function and urinalysis during and after anti-angiogenic therapy, even when the patient has remained..."

Clinical • Metastases • Breast Cancer • Hypertension • Nephrology • Oncology • Renal Disease • Solid Tumor

Newfangled Combination Azilsartan and Ceftriaxone Exhibited Potential Effects in In-Vitro and In-Vivo Models of Cerebral Ischemia: A Comprehensive Pharmacological Investigation. (PubMed, Ann Neurosci) - "The above combination significantly reversed the behavioural dysfunction in ischemic rats, which evidences the beneficial effects. The repurposing of anti-hypertensive, Azi, and antibiotic Cef combination demonstrated an excellent neuroprotective potential, mediating through ameliorating neuroinflammation, excitotoxicity and oxidative stress in in vitro OGD-induced astrocyte-neuron co-culture as well as cerebral ischemic rat model."

Journal • Preclinical • Cardiovascular • CNS Disorders • Inflammation

Efficacy and Safety of Sacubitril/Valsartan After Switching From Azilsartan in Essential Hypertensive Patients: Based on Home Blood Pressure Monitoring. (PubMed, J Clin Hypertens (Greenwich)) - "Twenty-one out of 27 patients accomplished recording of their nighttime HBP, and the morning-nighttime difference in systolic HBP was decreased (8.8 ± 13.5 to 3.9 ± 8.5 mmHg)(all p < 0.05 by repeated-measures ANOVA). In hypertensive patients, sacubitril/valsartan was generally well tolerated, except for causing hypotension, effectively controlled out-of-office BP, and decreased NT-proBNP."

Journal • Hypotension • NPPB

Identification of a Metastatic Clone in Human Undifferentiated Pleomorphic Sarcoma Reveals a Metastasis-Suppressing Therapy (AAOS 2026) - "This study provides direct evidence that a metastatic-clone subpopulation exists in human UPS tumors and is responsible for metastatic dissemination. Targeting AGTR2, a gene selectively expressed in this population, effectively suppresses metastasis in preclinical models. These findings suggest that therapies directed at metastatic subpopulations—using FDA-approved agents like Azilsartan—may represent a promising strategy to improve outcomes for patients with this otherwise difficult to treat sarcoma."

IO biomarker • Metastases • Cardiovascular • Hypertension • Lung Cancer • Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma • ESM1

Azilsartan prevents central modulation of BDNF and PPARγ in Alzheimer's pathology through amyloidogenic and inflammatory pathways: experimental and computational evidence. (PubMed, Inflammopharmacology) - "The results demonstrated that intranasal delivery of azilsartan significantly ameliorated cognitive decline when compared to standard drug donepezil, as evidenced from the behavioural tests, restored hippocampal oxidative balance (SOD, GSH, CAT), reduced lipid peroxidation (2.6-fold reduction in MDA levels compared to the AlCl3-intoxicated group), and increased neuronal count. To validate these findings, in silico molecular docking and dynamics simulations were conducted on the key markers TNFα, IL1β, PPARγ, BDNF, APP, and p-Tau, which showed strong and stable binding interactions with BDNF and PPARγ and moderate but persistent stabilization with APP and p-Tau, aligning with in vivo experimental outcomes. Therefore, the integrated computational and experimental evidence thus demonstrates that azilsartan exhibits neuroprotection, highlighting its potential as a therapeutic candidate for repurposing in Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • BDNF • IL1B • PPARG • TNFA

Azilsartan as a novel anti-ferriptotic agent via the upregulation of the Nrf2/HO-1/SLC7A11/GPX4 axis and downregulation of inflammatory pathways in folic acid-induced acute kidney injury in male mice. (PubMed, Toxicol Rep) - "Azilsartan confers potent protection against FA-induced AKI by activating the Nrf2/HO-1/SLC7A11/GPX4 axis, reducing lipid peroxidation, normalizing iron metabolism, and attenuating inflammation. These findings support azilsartan's potential as a repurposed therapy for ferroptosis-driven renal injury."

Journal • Preclinical • Acute Kidney Injury • Inflammation • Nephrology • Renal Disease • GPX4 • KIM1 • SLC7A11 • TFRC • TNFA

A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer. (PubMed, In Vivo) - "These findings emphasize that adequate BP control, rather than antihypertensive class, may be critical in managing Bev-induced proteinuria."

Clinical • Journal • Cardiovascular • Colorectal Cancer • Hypertension • Oncology • Renal Disease • Solid Tumor

Encapsulation-based enhancements in modern drug delivery systems. (PubMed, Int J Pharm) - "In addition, the pharmaceutical industry has commercialized many encapsulated drugs, such as anti-inflammatory (ibuprofen, dexamethasone), high blood pressure drugs (valsartan, azilsartan), proton pump inhibitors (lansoprazole), anti-cancer (carboplatin, carmustine, cisplatin, trastuzumab, cytarabine, paclitaxel, doxorubicin (DOX), vincristine) antiparasitic (amphotericin), antifungal (clotrimazole), and hormonal (melatonin (MLT))). It can render drugs more convenient and user-friendly for various therapeutic purposes and help to enhance their performance, functionality, and effectiveness. This comprehensive review examines the encapsulation technologies employed in the pharmaceutical industry, highlighting notable examples of encapsulated drugs that demonstrate their mechanism of action and potential therapeutic effects in vitro, in vivo, and through clinical trials, with relevance to various diseases."

Journal • Review • Cardiovascular • Hypertension • Oncology

Decoding the Neuroprotective Intervention of Angiotensin Receptor Blockers: A Multimodal Approach Using In Silico Network Pharmacology, Molecular Modeling, and In Vivo Validation of Key Markers. (PubMed, ACS Chem Neurosci) - "Building on these findings, this study sought to compare the activity of azilsartan with other commonly used ARBs, including telmisartan, olmesartan, valsartan, eprosartan, irbesartan, and candesartan, using an integrative network pharmacology approach. To experimentally validate these predictions, in vivo studies were conducted in a scopolamine-induced memory-impaired model, which demonstrated significant restoration of the levels of AKT1 and PIK3CA. These findings clearly demonstrate the PI3K/AKT modulating effects of azilsartan, reinforcing its repurposing potential in dementia and related disorders, thereby expanding novel therapeutic opportunities within this drug class."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • AKT1 • PIK3CA • PIK3CB

Azilsartan as an antihypertensive treatment in Japanese children under 6 years old: A phase 3 open-label long-term study. (PubMed, Pediatr Int) - "Azilsartan was generally well tolerated and associated with sustained BP reductions over 52 weeks in nine Japanese pediatric patients with hypertension. No new safety signals were identified. Our results indicate that azilsartan can be a therapeutic option for managing pediatric hypertension, potentially improving long-term cardiovascular outcomes."

Journal • P3 data • Acute Kidney Injury • Cardiovascular • Hematological Disorders • Hypertension • Nephrology • Pediatrics • Renal Disease

Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report. (PubMed, Am J Case Rep) - "CASE REPORT A 63-year-old woman with stage 3b diabetic kidney disease and depressive disorder was prescribed dulaglutide 0.75 mg/week subcutaneously in August 2023 due to persistent albuminuria despite receiving the maximum tolerated dose of azilsartan...Azilsartan and chlorthalidone could then be successfully rechallenged...Nevertheless, this does not prevent the prescription of GLP-1 RAs to alleviate DKD progression in certain patients. Treatment includes drug discontinuation and steroid therapy in non-responders."

Journal • Acute Kidney Injury • CNS Disorders • Depression • Diabetic Nephropathy • Infectious Disease • Nephrology • Psychiatry • Renal Disease

Molecular mechanisms underlying cyclophosphamide-induced ovarian injury and protective strategies. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Quercetin, resveratrol, berberine, curcumin, irbesartan, mirtazapine, sildenafil, atorvastatin, donepezil, cilostazol, moxibustion, LCZ696, buspirone, levomilnacipran, melatonin, diosmin, and azilsartan are some of the agents that may protect against ovarian injury caused by CP, as shown in Graphical abstract. Our goal in writing this study is to provide a concise overview of the possible redox molecular pathways that cause ovarian harm in CP and how to potentially ameliorate them. Finally, investigation into these molecular pathways may pave the way for early ovarian damage relief and for the development of different agent strategies to alleviate CP-mediated POF."

Journal • Review • Inflammation • Oncology • Women's Health • IL6 • NLRP3 • TNFA

A Case of Thiazide-Induced Hyponatremia in an Elderly Patient. (PubMed, Cureus) - "She was previously taking famotidine, atorvastatin, losartan, triamterene, and atenolol to manage her hypertension and hyperlipidemia. Her medication was changed to azilsartan-chlorthalidone, amlodipine, and carvedilol one week before presentation for better management of her blood pressure...She was followed for two weeks and had been doing well. This case highlights the importance of taking a detailed history and examination, and taking into account drugs as a source of hyponatremia in elderly patients."

Journal • Cardiovascular • Dyslipidemia • Heart Failure • Hypertension

In brief: Low-dose chlorthalidone (HemiClor) for hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Hypertension

CHRONIC KIDNEY DISEASE PROGRESSION ASSESSMENT ON THE BASIS OF COMPLEX TREATMENT (ERA 2025) - "All examined patients individually take the required amount of azilsartan for antihypertensive purposes (40-80 mg/day), depending on the level of hypertension... 1. Application of "additional azylsartan and ethylmetalhydroxypyridine succinate" to conventional treatment slows the development of chronic kidney disease. 2."

Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

First Description of Sprue-Like Enteropathy due to Azilsartan: A Case Report. (PubMed, Case Rep Gastroenterol) - "This case illustrates sprue-like enteropathy as a potential side effect of azilsartan, emphasizing to consider this differential diagnosis in ARB-treated patients with chronic diarrhea. The causality of our findings was confirmed by drug de-challenge and re-challenge resulting in typical histological changes."

Journal • Celiac Disease • Immunology

Enhancing Home Blood Pressure Management: Implementation of the Sacubitril/Valsartan Treatment in Practical Clinical Settings. (PubMed, JMA J) - "These effects were maintained for 48 weeks. The switch from azilsartan to sacubitril/valsartan treatment resulted in a significant improvement in the achievement of home BP targets, which is consistent with our goal of refining hypertension management strategies in practical clinical settings."

Journal • Cardiovascular • Hypertension

Multidisciplinary intervention for adverse events associated with ATZ + BEV therapy: a case report. (PubMed, J Pharm Health Care Sci) - "The pathophysiology of irAE-induced peripheral neuropathy associated with immune checkpoint inhibitors remains poorly understood. This case underscores the challenges of managing irAE-related neuropathy, which may exhibit limited responsiveness to conventional treatments. Early detection, timely intervention, and multidisciplinary approaches are crucial for optimizing patient outcomes and mitigating the impact of severe side effects."

Adverse events • Journal • Cardiovascular • Hepatocellular Cancer • Hypertension • Oncology • Pain • Solid Tumor

Angiotensin receptor blockers and drug-induced liver injury: a cohort study using electronic-health records-based common data model database (EASL 2025) - "In this study, patients were designated to treatment groups according to the ARB prescribed at cohort entry, i.e., azilsartan, eprosartan, telmisartan, fimasartan, valsartan, olmesartan, losartan, irbesartan, or candesartan. Our findings provide insights to the methods for detecting DILI using real-world data and enhance understanding of the variations in risk of DILI among individuals using different ARBs."

Hepatology • Liver Failure

Azilsartan Confers Protection Against Kainic Acid-Induced Hippocampal Neuron Damage by Upregulating Sirt3/Sod2 Pathway. (PubMed, Dev Neurobiol) - "Besides, Azilsartan administration activated Sirt3 and Sod2 expression in KA-stimulated HT-22 cells, and Sirt3 depletion partially blocked the impacts of Azilsartan on Sirt3/Sod2 pathway, mitochondrial damage, viability, and apoptosis in HT-22 cells exposed to KA. Collectively, Azilsartan might act as a neuroprotective agent in treating epilepsy through the activation of Sirt3/Sod2 pathway."

Journal • CNS Disorders • Epilepsy • SIRT3 • SOD2

Angiotensin II Promotes Osteocyte RANKL Expression via AT1R Activation. (PubMed, Biomedicines) - "These effects were abrogated by azilsartan, a blocker targeting Ang II type 1 receptors (AT1R). p38 and ERK1/2 in the MAPK pathway were also activated by Ang II. Ang II enhances osteocyte-mediated osteoclastogenesis via AT1R activation, highlighting its potential as a therapeutic target for bone diseases."

Journal • Cardiovascular • Hypertension • Orthopedics • CSF1 • TNFSF11

ACUTE KIDNEY INJURY FROM MONONUCLEAR CELL-PREDOMINATED INTERSTITIAL NEPHRITIS AFTER THE INTRODUCTION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS: A CASE REPORT (ISN-WCN 2025) - "Results A 63-year-old female with diabetic kidney disease in stage 3b and depressive disorder was prescribed dulaglutide 0.75 mg per week subcutaneously in August 2023 due to persistent albuminuria despite the maximum tolerated dose of azilsartan...Azilsartan and chlorthalidone could be successfully rechallenged after almost complete recovery of kidney function...Nevertheless, this does not prevent the prescription of GLP-1 RAs to alleviate the DKD progression in indicated patients. This abstract was also submitted for the Nephrology Society of Thailand Annual Meeting 2024 congress."

Case report • Clinical • Acute Kidney Injury • Chronic Kidney Disease • CNS Disorders • Depression • Diabetes • Diabetic Nephropathy • Infectious Disease • Metabolic Disorders • Nephrology • Psychiatry • Renal Disease

In silico and in vitro assessments of the mutagenicity of the azilsartan photoproduct. (PubMed, Mutat Res Genet Toxicol Environ Mutagen) - "However, APP was not mutagenic in the Ames test. Density functional theory (DFT) calculations showed that APP cannot intercalate into DNA, due to its nonplanar structure, resulting from steric hindrance of its phenanthridine and benzimidazole moieties."

Journal • Preclinical

Efficacy and safety of azilsartan in the treatment of OSAS-related hypertension combined with coronary artery disease: a randomized controlled double-blind clinical trial (ChiCTR) - P4 | N=280 | Not yet recruiting | Sponsor: Southern Medical University Southern Hospital; Southern Medical University Southern Hospital

New P4 trial • Cardiovascular • Coronary Artery Disease • Hypertension

A Bioequivalence Study of Azilsartan in Healthy Chinese Subjects. (PubMed, Clin Pharmacol Drug Dev) - "No serious adverse events or unexpected adverse drug reactions were observed. In conclusion, the test and reference preparations of azilsartan tablets demonstrate bioequivalence and good safety in healthy Chinese subjects under fasting and postprandial conditions."

Journal • Cardiovascular • Congestive Heart Failure • Diabetic Nephropathy • Heart Failure • Hypertension • Nephrology • Renal Disease